The FDA granted approval to Eli Lilly and Company’s mirikizumab-mrkz (Omvoh) for Crohn disease, expanding its treatment reach ...

The Food and Drug Administration has approved Omvoh (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn disease in adults.

Sales of Eli Lilly's lead drug, tirzepatide, which it markets as Zepbound for weight loss and Mounjaro for diabetes, leapt up to a combined $5.4 billion in the fourth quarter. That's some amazing ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 472.57% and ...

The FDA has approved Omvoh (mirikizumab-mrkz) for treating moderately to severely active Crohn’s disease in adults. Clinical ...

The U.S. Food and Drug Administration has approved Eli Lilly's Omvoh (mirikizumab-mrkz) for the treatment of moderately to ...

Omvoh demonstrated 53% clinical remission and 46% endoscopic response in Crohn's patients after one year, outperforming ...

Indianapolis-based Lilly announced Thursday that the U.S. Food and Drug Administration has approved Omvoh for the treatment ...

The U.S. Food and Drug Administration has approved Omvoh (mirikizumab-mrkz) for the treatment of moderately to sever ...

More than half (53%) of patients reached remission after one year of Omvoh treatment and 46% experienced healing of the ...

N-Power Medicine, backed by Merck GHI, announced the acquisition of Syapse Holdings. Samsung Biologics and LigaChem extended their ADC services deal. Publicis Worldwide merged with Leo Burnett to form ...

2024 revenue is expected to be approximately $45.0 billion for the full year, $4.0 billion above the midpoint of first-time 2024 financial guidance Q4 2024 revenue is expected to be approximately ...